

Company: FluCell

Project: Universal Flu Vaccine

Authors: Marissa Stanvick and Elizabeth Armstrong

Overview: FluCell is dedicated to the development of a novel universal flu vaccine that is more effective than any other flu vaccine on the market. FluCell will be administered as an adjuvant to the traditional influenza vaccine. Our adjuvant delivers a conserved epitope from influenza A strains to activate a T cell response, in addition to the traditional antibody response. This T cell response is cross-protective from multiple strains of influenza. Traditional flu vaccines leave people at risk due to low effectiveness and antigenic shifts of the predominant flu strain each year. FluCell could change all of that.

At FluCell, our mission is to:

- Develop high quality flu vaccines that protect against a wide range of influenza strains to decrease the number of illnesses, hospitalizations, and deaths caused by the flu.
- Increase the rate of vaccination in the US by educating people about the importance of flu vaccines.
- Equip people with the right tools so they can avoid the flu and spend time on what actually matters.